Aim. To investigate the association between monocyte CD163 and insulin resistance in patients with type 2 diabetes. Methods. One\nhundred sixty-six patients with type 2 diabetes without inflammatory or chronic kidney disease were recruited. The monocyte\nCD163 levels were measured by flow cytometry and soluble CD163 (sCD163) by ELISA. Insulin resistance was evaluated by the\nindex of the homeostasis model assessment (HOMA-R). Results. The median sCD163 and monocyte CD163 expression levels\nwere 582.9 (472.4ââ?¬â??720.0) ng/ml and 6061 (4486ââ?¬â??7876) mean fluorescent intensity (MFI), respectively. In a simple regression\nanalysis, monocyte CD163 was inversely correlated with log [HOMA-R] (r = ââ?¬â??0 257, p = 0 010), and sCD163 was positively\ncorrelated with log [HOMA-R] (r = 0 198, p = 0 042). In multiple regression analyses, monocyte CD163 was an independent\ncontributor to log [HOMA-R] (Ã?² = ââ?¬â??0 220, p = 0 020) even after adjustment of various clinical factors for HOMA-R (R2 = 0 281,\np = 0 001), whereas sCD163 was not. Conclusions. Monocyte surface CD163 expression levels were more significantly associated\nwith insulin resistance than sCD163 in patients with type 2 diabetes, suggesting a novel pathophysiological role of CD163.
Loading....